Asthma Therapeutics Market Report Size Analysis:

The Asthma therapeutics Market size was valued at USD 28.15 billion in 2024 and is expected to reach USD 41.79 billion by 2032, growing at a CAGR of 5.07% over the forecast period of 2025-2032.

To Get more information on Asthma therapeutics Market - Request Free Sample Report

Asthma is a chronic respiratory condition whose frequency is gradually increasing in response to urbanization, air pollution, and climate change, affecting millions of people globally.

For instance, the World Health Organization (WHO) estimates that asthma affects over 262 million people globally and results in more than 450,000 deaths yearly.

The Centers for Disease Control and Prevention (CDC) estimated that, in 2024, 25 million Americans, including 6 million children, were suffering from asthma. Reflecting a strong regulatory drive to increase treatment alternatives, the U.S. Food and Drug Administration (FDA) has lately sped approvals for new asthma therapeutics. Together with rising healthcare expenditure and better diagnosis techniques, these government-led projects are driving strong asthma therapeutics market growth and influencing new asthma therapeutics market trends.

High asthma prevalence, good reimbursement policies, and quick acceptance of biologics for asthma and digital health solutions fuel the leadership in the global Asthma therapeutics market. With a CAGR of 8.46%, the U.S. asthma therapeutics market alone is expected to rise to USD 16.31 billion by 2032 from USD 11.18 billion in 2024. The ongoing FDA approvals for new drugs, including the recent approval of depemokimab for review as an ultra-long-acting biologic for type 2 inflammation asthma, and the clearance of new inhaled therapies, such as frevecitinib for patients inadequately controlled by standard treatments, further support the predominance of the U.S. market.

With over 262 million affected and more than 450,000 annual fatalities globally, asthma continues to be a serious public health issue, according to the WHO. In 2024, the CDC estimates 25 million Americans, including 6 million children, have asthma. The FDA has stepped up its initiatives to hasten the approval of biologics and smart inhalers, among sophisticated asthma therapies. While rising healthcare expenditure and better diagnosis techniques continue to improve outcomes in the asthma therapeutics market, national agencies and organizations, such as the Asthma and Allergy Foundation of America (AAFA) are driving awareness and access to treatment.

Asthma Therapeutics Market Dynamics:

Drivers:

• Asthma Therapeutics is Transformed, and Clinical Outcomes are Improved by Biologics and Personalized Medicine Innovations

Offering customized solutions for patients with severe or treatment-resistant forms of the condition, breakthroughs in biologics and personalized medicine are transforming asthma therapy. The U.S. FDA's approval of the biologics license application for depemokimab, which should be approved, will become the first ultra-long-acting biologic for asthma and will need just two doses annually. Depemokimab greatly lessened asthma flare-ups and hospitalizations in individuals with type 2 inflammation, according to clinical trials (SWIFT and ANCHOR), therefore underscoring the potential of focused treatments to improve patient outcomes and adherence.

Furthermore, expected to boost patient access and lower costs for those with moderate to severe asthma is the FDA's approval of Omlyclo (omalizumab-igec) as the first interchangeable biosimilar to Xolair. Digital health technology, such as smart inhalers and remote monitoring systems, which are progressively embraced in North America and Europe to maximize adherence and enable data-driven, individualized treatment, which further complements these developments. Driven by better access to biologics, digital health advancements, and value-based reimbursement models linking drug cost to patient outcomes, the U.S. asthma treatment market is expected to expand at a noteworthy CAGR.  These scientific and legal turning points are drastically changing the asthma therapeutics scene and increasing the availability and efficacy of advanced, customized treatment.

Restraints:

• Underdiagnosis and Poor Adherence Undermine Asthma Therapeutics Effectiveness and Limit Market Expansion

Persistent underdiagnosis and suboptimal adherence to asthma therapies significantly undermine the effectiveness of available treatments and restrict market growth. Despite advancements in diagnosis and therapy, many individuals remain undiagnosed or are not optimally managed, resulting in preventable exacerbations and increased healthcare utilization. In the U.S., asthma-related mortality, which had been declining, saw a sharp increase from 2018 to 2020, with notable rise among younger age groups and persistent disparities affecting females and non-Hispanic Black populations.

Poor adherence to prescribed regimens is exacerbated by complex dosing schedules, side effects, and inadequate patient education. The integration of digital health solutions, such as smart inhalers and remote monitoring systems, is beginning to address these challenges by providing real-time adherence tracking and personalized feedback. However, disparities in access to digital tools and healthcare infrastructure, especially in rural and low-resource settings, continue to limit their impact. Addressing these issues through widespread education, improved diagnostic protocols, and expanded digital health adoption is essential for maximizing the benefits of Asthma Therapeutics and achieving sustainable market growth.

Asthma Therapeutics Market Segmentation Analysis:

By Drug Class

The anti-inflammatory segment dominated the market with a revenue share of 61% in 2024, particularly for lowering airway inflammation and thereby preventing exacerbations. Anti-inflammatory medications, especially inhaled corticosteroids (ICS), are fundamental in asthma treatment. Government figures showing the increasing frequency of severe and allergic asthma, particularly in young populations, support the leadership in this segment.

For instance, the U.S. FDA recently approved several biologics for asthma, including depemokimab-an ultra-long-acting IL-5 inhibitor for type 2 inflammation, also under review for use in children.

Biologics for asthma, including omalizumab and mepolizumab, are increasingly prescribed for severe and allergic asthma therapeutics market segments, offering targeted control of airway inflammation and reducing hospitalizations. Recent advances include the FDA's approval of novel medications, including frevecitinib, which targets individuals, inadequately controlled by long-acting beta agonists (LABAs) and traditional ICS. Particularly for people with allergen-triggered asthma or eosinophilic phenotypes, these developments are revolutionizing choices for the treatment of severe asthma.

Expected to achieve the fastest CAGR of 5.57% over the projected period are combination asthma therapies, especially those combining ICS with LABAs or triple combos (ICS/LABA/LAMA). Superior efficacy drives this since combination treatments treat bronchoconstriction and airway inflammation, therefore enhancing the results for patients using treatments for severe and allergic asthma. Reflecting good clinical evidence, national and international recommendations now call for combination asthma therapies for moderate-to-severe and pediatric asthma drugs. The FDA’s recent approval of combination inhalers and biologics, such as AstraZeneca's Tezepelumab, which showed a notable drop in Phase III studies' exacerbations. Targeting treatments and smart inhalers, which allow customised dose and adherence tracking, helps to justify the trend towards individualised asthma treatment.

By product

Inhalers remain the dominant segment in the market and held the highest asthma therapeutics share in 2024, due to their convenience, portability, and quick relief for both chronic respiratory disease treatments and acute exacerbations. The standard of treatment is now inhaled corticosteroids (ICS), bronchodilator drugs, and combination asthma treatments used widely through inhalers. Recent government statistics and legislative changes show how quickly smart inhalers are being adopted. The global smart inhalers market is estimated to reach USD 5.30 billion in 2032 and increase at a CAGR of 14.01% during the forecast period. Recently approved by the U.S. FDA, novel inhaled treatments and combination inhalers, include Trelegy Ellipta for patients not responding to dual therapy, drive market development.  As the CDC and AAFA underline, inhalers are still the recommended option for juvenile asthma medications because of their simplicity and dose precision.

Nebulizers are expected to register the fastest CAGR, driven by their essential part in severe asthma treatment options and for small children or elderly patients struggling with inhaler technique. More portable and effective nebulizers, due to technological developments, have improved access for severe instances and asthma driven by allergens. Government projects, including nebulizer donation campaigns in India and the acceptance of nebulizers in home and hospital environments, are accelerating segment growth. Targeting individuals whose asthma is not sufficiently managed by current inhaled maintenance medications, the FDA's clearance of frevecitinib for clinical trials in 2025 shows continuous innovation in inhalation drug delivery for both inhalers and nebulizers.

By Route of Administration

The inhaled segment dominated the asthma treatment market, comprising 46% of the asthma therapeutics market share in 2024. The segment’s growth is propelled by the inhaled corticosteroids (ICS) to the lungs, directly provide bronchodilator drugs and minimize systemic side effects, making inhaled treatments preferred for quick relief and minimizing side effects. For both severe asthma treatment choices and the allergic asthma therapeutics market, the FDA and international guidelines advise inhaled treatments as first-line therapy. The development of digital adherence tools and smart inhalers improves patient outcomes and supports tailored asthma treatment.

Particularly for pediatric asthma drugs and those who find it difficult to use inhalers, the oral segment is expected to see the largest asthma therapeutics market growth. While systemic corticosteroids are crucial for severe asthma treatment choices and acute exacerbations, leukotriene receptor antagonists are extensively prescribed for the allergic asthma therapeutics market, especially in children. Under development are new oral immunomodulatory drugs and biologics for asthma, hence increasing the available treatments for refractory cases.  Recent advances include the FDA's evaluation of oral and inhaled biologics and the inclusion of oral treatments into combo regimens for complete management of asthma.

Asthma Therapeutics Market Regional Analysis:

With a 51% market share in 2024, North America dominated the global asthma therapeutics market. The region’s dominance is driven by the strong research and development investment, superior healthcare infrastructure, and high asthma frequency, the U.S. leads this region.  The U.S. asthma therapeutics market alone was valued at USD 11.18 billion in 2024, and is expected to grow at a CAGR of 4.84% during the forecast period.

Strong reimbursement systems, high diagnostic rates, and broad availability of advanced treatments as smart inhalers and biologics, help to justify this supremacy.  By accelerating the approval of sophisticated asthma medications, the U.S. FDA has been proactive, thus strengthening its leadership in the field of asthma therapy. Furthermore, greatly enhanced patient adherence and outcomes are continuous awareness programs headed by groups, such as the Asthma and Allergy Foundation of America (AAFA) and the incorporation of digital health solutions, such as smart inhalers and telemedicine.

Asia Pacific is predicted to be the fastest-growing region in the asthma therapeutics market with a 5.7% CAGR over the forecast period. Attributed to rapid urbanization, increasing air pollution levels, and better diagnostic techniques, countries including China and India are witnessing a boost in recorded asthma cases. Government projects, including national asthma control campaigns and more respiratory care funding, are driving market development even more. Along with the increasing presence of global pharmaceutical businesses, the area is also seeing more availability of generic asthma drugs.  Asia Pacific is destined to become a major development engine for the worldwide Asthma Therapeutics sector as economic conditions improve, public knowledge of asthma management rises, and healthcare access grows.

In 2024 Europe accounted for a significant share of the global asthma therapeutics market. The creation of creative targeted drugs drives the expansion of the area, especially as limits in conventional treatments become clearer. Well-established healthcare systems, high diagnostic rates, government-supported access to sophisticated biologics, and combo treatments help European nations to grow. European regulatory bodies keep pushing for the acceptance of fresh treatment approaches, thereby promoting market expansion and patient outcomes.

Get Customized Report as per Your Business Requirement - Enquiry Now

Asthma Therapeutics Market Key Players:

The key asthma therapeutics companies are GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Covis Pharma, F. Hoffmann-La Roche Ltd., BD, AstraZeneca, Sanofi, Koninklijke Philips N.V., Boehringer Ingelheim International GmbH, and others.

Recent Developments in the Asthma Therapeutics Market:

• Reflecting the agency's dedication to hastening access to breakthrough medications, GlaxoSmithKline got enhanced FDA approval for its triple-combining inhaler Trelegy Ellipta in January 2025, now authorized for asthma patients resistant to dual treatment.

• Following clearance from the European Medicines Agency (EMA), Sanofi and Regeneron debuted a new dose formulation of Dupixent® (dupilumab), an IL-4 and IL-13-targeting biologic, enhancing access for patients with moderate-to-severe asthma in September 2024.

• In January 2025, GlaxoSmithKline received expanded FDA approval for its triple-combination inhaler Trelegy Ellipta, now indicated for asthma patients unresponsive to dual therapy, reflecting the agency’s commitment to accelerating access to advanced therapies.